Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biohit

2.53 EUR+1.61 %4.9, 17.29
4,974 following

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
+1.61 %
-8.99 %
-5.60 %
+1.20 %
-31.44 %
-8.99 %
+26.50 %
+17.67 %
-51.35 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
38.47M EUR
Turnover
11.56K EUR
P/E (adj.) (26e)
14.92
EV/EBIT (adj.) (26e)
12.11
P/B (26e)
2.18
EV/S (26e)
2.21
Dividend yield-% (26e)
2.01 %
Coverage
Recommendation
Accumulate
Target price
3.30 EUR
Updated
05.08.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 06.08.2026

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
Nasdaq Company News Uusi tieteellinen katsaus tukee biomarkkereihin perustuvaa mahasyöpäriskin... New scientific review supports biomarker-based assessment of gastric cancer risk and determination of the need for gastroscopy
yesterday
by Ashwanga
4
Syrjänen is just under 80 years old, so there’s hardly any shadowy mysticism related to Biohit here, and I’m not going to guess what personal reasons there might be. Anyone can create scenarios for the background.
9/2/2026, 8:56 PM
by Tunturisusi
4
That Western validation mentioned in the article seems to refer to a few studies on the use of pepsinogen and H. pylori in screening, not to Gastropanel as such. According to the authors, in Western healthcare systems, the strongest evidence supports one-time pepsinogen and H. pylori...
8/31/2026, 10:09 AM
by Antti Siltanen
4
Here is additional information from Antti: “that Western validation refers to a few studies on the use of pepsinogen and H. pylori, not GastroPanel as such” Wrong. Quote from the paper, p. 4: “The revised ABC method, marketed as GastroPanel, adds G-17 to improve specificity and to...
8/31/2026, 11:05 AM
by Miikka
1
Alright, fair enough, personal reasons probably suffice for everyone, thanks for pointing that out.
9/2/2026, 4:03 PM
by Ehemot
0
You might want to read the article before asking… Personal reasons are hardly related to the company.
9/2/2026, 2:37 PM
by PaulKo
0
Was the reason given? Or is this going to be swept under the rug as well?
9/2/2026, 2:28 PM
by Ehemot
0
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release03.09.2026, 11.00

New scientific review supports non-invasive biomarker-based triage for gastric cancer risk

Biohit
Regulatory press release02.09.2026, 16.00

Biohit Oyj: Kari Syrjänen resigns as Chair of the Board of Directors

Biohit
Biohit: GastroPanel Quick Test also works during proton pump inhibitor therapy
Analyst Comment19.08.2026, 08.27 by
Antti Siltanen

Biohit: GastroPanel Quick Test also works during proton pump inhibitor therapy

Proton pump inhibitors do not affect the accuracy of the GastroPanel Quick Test.

Biohit

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Biohit H1'26: Strong earnings clouded by weak cash flow
Research06.08.2026, 09.50 by
Antti Siltanen

Biohit H1'26: Strong earnings clouded by weak cash flow

Biohit's reported earnings were excellent, but cash flowed out of the company in the first half of the year.

Biohit
Regulatory press release05.08.2026, 08.30

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2026 (unaudited) 

Biohit
Biohit H1'26 preview: Moderate growth against weak comparison period
Analyst Comment31.07.2026, 07.23 by
Antti Siltanen

Biohit H1'26 preview: Moderate growth against weak comparison period

Chile's screening program accelerates revenue growth to 8% in our H1 estimate.

Biohit
Biohit: Sold on summer sale
Research29.06.2026, 08.00 by
Antti Siltanen

Biohit: Sold on summer sale

The stock's valuation has fallen to a rather low level.

Biohit
Regulatory press release05.06.2026, 17.00

Constitutive meeting of Biohit Oyj’s Board of Directors

Biohit
Regulatory press release03.06.2026, 17.00

Decisions of the Annual General Meeting of Biohit Oyj

Biohit
Regulatory press release06.05.2026, 14.45

Correction: Notice of Biohit Oyj’s Annual General Meeting

Biohit
Regulatory press release06.05.2026, 14.06

Notice of Biohit Oyj’s Annual General Meeting

Biohit
Regulatory press release06.05.2026, 14.00

Notice of Biohit Oyj’s Annual General Meeting

Biohit
Study: Biohit's GastroPanel reduced waiting lists
Analyst Comment22.04.2026, 07.26 by
Antti Siltanen

Study: Biohit's GastroPanel reduced waiting lists

Endoscopy wait times were reduced by 87%.

Biohit
Press release21.04.2026, 13.00

A peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy waiting lists

Biohit
Regulatory press release01.04.2026, 13.00

Biohit Plc B-shares Subscribed with Stock Options I 2021D

Biohit
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026, 11.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release18.03.2026, 08.30

Publication of Biohit Oyj Annual Report 2025

Biohit
Regulatory press release18.03.2026, 08.30

Publication of Biohit Oyj Remuneration Report 2025

Biohit
Press release11.03.2026, 12.00

Change in the Biohit Oyj Management Team

Biohit
Biohit H2'25: Strong earnings – more moderate growth outlook
Research12.02.2026, 09.16 by
Antti Siltanen

Biohit H2'25: Strong earnings – more moderate growth outlook

Biohit’s revenue was in line with our estimate, and earnings exceeded it.

Biohit